ClinicalTrials.gg
RecruitingNCT03516968OBEVIDOSUpdated Jun 13, 2025

Monthly Boluses Versus Daily Doses for Correcting Blood Vitamin D Deficit in Obese Children and Adolescents

A Phase 3 interventional study of Monthly bolus of cholecalciferol per os and Daily dose of cholecalciferol per os in Obesity, Childhood, sponsored by Hospices Civils de Lyon. Recruiting at 4 sites in France. Open to participants aged 5 Years to 18 Years. Per ClinicalTrials.gov, last updated 2025-06-13.

Sponsored by Hospices Civils de Lyon · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2023; still recruiting 2 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
68
Allocation
Randomized
Ages
5 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 26 studies in Pediatric Obesity with a site in France — 3 open to participants now, 4 under way, 1 of them phase 3. Pediatric Obesity · France.

Planned enrollment
3rd of 17
68 · median 30
Started
2023
with 1 other
Phase 3
Only one
of the 26
Registered
10th of 26
by date
Lead sponsor
2 of 26
Hospices Civils de Lyon

Among the 26 studies in Pediatric Obesity with a site in France, this one is the 3rd largest by planned enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2023, is the only one in phase 3, and was the 10th registered.

Pediatric Obesity

1,132 studies on the registry are indexed under Pediatric Obesity; 183 are open to participants now.

Browse Pediatric Obesity studies →

Open to participants now

3 of the 26 studies in Pediatric Obesity with a site in France are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 119 Pediatric Obesity studies recruiting now, 16 (13%) set no upper age limit and 101 (85%) stop at 75 or younger; 110 take children under 18; 67 take healthy volunteers.

This study: 5 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Pediatric Obesity with a site in France, or all of them as a file.
02

Study summary

Childhood obesity is one of the most serious public health challenges of the 21st century, with an increasing prevalence over time in developed countries. Overweight and obese children and adolescents are likely to remain so into adulthood and to develop chronic diseases at a young age, such as diabetes and cardiovascular disease.

Obese patients, whether adults or children, are likely to have low serum vitamin D levels due to sequestration and/or volumetric dilution of this fat-soluble vitamin in adipose tissue. Studies have established a link between vitamin D deficiency or insufficiency and chronic diseases such as hypertension, type 2 diabetes and other metabolic problems.

Determining physiological 25(OH)D levels to ensure optimal phosphocalcic metabolism and bone mineralisation requires the use of functional markers: parathyroid hormone (PTH) levels, assessment of the intestinal calcium absorption fraction, assessment of bone mineral density and bone mineral content using absorptiometry.

Vitamin D deficiency leads to malabsorption of calcium and phosphate in the digestive tract, with concentrations, especially of calcium, tending to fall in plasma, resulting in hypersecretion of PTH, which mobilises bone calcium to maintain subnormal blood calcium levels.

Each unit increase in BMI is associated with lower serum vitamin D concentrations: given these low concentrations in this population associated with the risk of developing pathologies, it is important to ensure adequate vitamin D supplementation.

The latest paediatric recommendations recommend, for children aged between 1 and 18 with vitamin D deficiency, a supplement of 2,000 IU/day for at least 6 weeks or a bolus of 50,000 IU once a week for at least 6 weeks.

There are different dosage regimens for the replacement of vitamin D deficiency depending on the country: there is a lack of data on the appropriate dosage and administration regimens for vitamin D supplementation in cases of deficiency, particularly in obese children and adolescents. A prospective, randomised clinical trial will make it possible to define the vitamin D supplementation regimen best suited to increasing serum vitamin D levels in these children and adolescents suffering from obesity.

03

Conditions studied

  • Obesity, Childhood

Keywords

  • Obesity
  • Vitamin D deficiency,
  • supplementation,
  • Child
  • Adolescent
04

Who can participate

Ages eligible
5 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged between 5 to 18 year-old
  • Being obese ( >97th percentile, > IOTF 30, for age and gender using the WHO references)
  • Patients (parents) having given their
  • Patient having insurance from the national health system

Exclusion criteria

Exclusion Criteria:

Children will be excluded from the study if:

  • Symptomatic vitamin D deficiency (tetany, muscular hypotonia, hypocalcaemic seizure)
  • Vitamin D supplementation in the 3 months preceding the inclusion visit (V1)
  • Signs of rickets at the X-ray (osteopenia and cortical thinning of the long bones, stress fractures, and metaphyseal widening and fraying)
  • Chronic disease such as granulomatous conditions, Williams syndrome, or hypothyroidism predisposing to hypocalcaemia or in case of hypercalcaemia (calcium > 2.65 mmol/L), liver/kidney disease, malabsorption diseases;
  • Hypercalciuria (urinary Calcium/Creatinine > 0.7 mmol/mmol), calcium nephrolithiasis, hypervitaminosis D (25-(OH)D > 250 nmol/L); nephrocalcinosis;
  • Ongoing treatment with anticonvulsants/barbiturates or which increase the catabolism of 25(OH)D;
  • Ongoing treatment with thiazides diuretics which reduce urinary excretion of calcium;
  • to the class of drugs under study, e.g. known or allergy to class of drugs or the product;
  • Pregnancy, breastfeeding;
  • Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant;
  • Simultaneous enrolment to another study which could influence the results of the current study;
  • Patient under legal protection or deprived of liberty.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
68 participants (estimated)

Study arms

  • Experimental
    Monthly bolus arm

    Drug: Monthly bolus of cholecalciferol per os

  • Experimental
    Daily arm

    Drug: Daily dose of cholecalciferol per os

Interventions

  • DrugMonthly bolus of cholecalciferol per os

    Bolus therapy: first 50 000 IU and a second 50 IU after 6 weeks

  • DrugDaily dose of cholecalciferol per os

    Daily substitution, 1200 IU per day (4 drops), for 3 months

06

What researchers measure

Primary outcomes

  1. Proportion of patients reaching the therapeutic target defined as vitamin D (25(OH)D) serum level ≥ 50 nmol/L and < 120 nmol/L

    Vitamin D (25OH)D) serum level

    Time frame: Month 3

Secondary outcomes

  1. calcium dosages

    blood safety dosages

    Time frame: Month 3

  2. phosphore dosages

    blood safety dosages

    Time frame: Month 3

  3. vitamin D (25(OH)D) dosages

    blood safety dosages

    Time frame: Month 3

  4. urinary calcium

    urinary safety dosages

    Time frame: Month 3

  5. creatinin

    urinary safety dosages

    Time frame: Month 3

  6. Treatment compliance

    amount of treatment taken (Daily arm: patient diary and weighting of returned treatment at M3. Bolus arm: description of taken ampoules after hospital dosing (number taken, empty or not))

    Time frame: Month 3

  7. Evaluation of influence of type of skin on study results

    assessed a questionnaire

    Time frame: Month 3

  8. Evaluation of influence of physical activity on study results

    assessed by a questionnaire

    Time frame: Month 3

  9. Evaluation of influence of sun exposure on study results

    assessed by a questionnaire

    Time frame: Month 3

  10. Evaluation of influence of alimentary intakes on study results

    assessed by questionnaires

    Time frame: Month 3

  11. Bone mineral density description (DXA)

    Bone mineral density

    Time frame: Day 1

  12. Evaluation of the PTH variation

    PTH serum level

    Time frame: Month 3

  13. Comparison bone mineral density (DXA) with a preexisting cohort

    Bone mineral density (DXA)

    Time frame: Day 1

07

Study locations

2 of 4 sites recruiting
  • Centre d'Investigation Clinique de LYON - CIC 1407- Groupement Hospitalier Est / Hospices Civils de Lyon
    Bron, 69677, France
    Recruiting
  • Service d'endocrinologie et métabolisme pédiatrique, Hôpital Femme Mère Enfant
    Bron, 69677, France
    Recruiting
  • Service d'Endocrinologie Pédiatrique CHU de Clermont-Ferrand
    Clermont-Ferrand, 63000, France
    Not yet recruiting
  • Centre Médical Infantile de Romagnat
    Romagnat, 63540, France
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2023 (actual). Primary completion is estimated for Mar 2027, 39 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2018
First posted
May 7, 2018
StartActual
Dec 4, 2023
Primary completionEst.
Mar 2027
CompletionEst.
Mar 2027
Last update
Jun 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03516968
Responsible party
Sponsor
First posted
May 7, 2018
Start date
Dec 4, 2023
Primary completion
Mar 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Jun 13, 2025

Study contacts

Carine Villanueva, MD
Contact
carine.villanueva@chu-lyon.fr
4 27 85 53 28 ext. +33
Carine Villanueva
principal investigator · Hospices Civils de Lyon

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion